Matches 1 - 50 out of 145 1 2 3 >


Match Document Document Title
DE102019000490A1 Use of oligonucleotides for the treatment of tumors  
The invention relates to the use of a tumor-effective oligonucleotide in tumor patients after complete or partial resection or ablation of a solid tumor of this patient, by applying it in a body...
DE102018114467A1 Invention regarding prophylaxis and therapy against NPC-1 sensitive viruses  
The invention discloses an agent for therapy and prophylaxis against NPC-1 sensitive viruses such as Ebola viruses, HIV, dengue and Marburg viruses. It comprises at least one antisense...
DE102017100317A1 Nanostructured carrier system for gene delivery  
The invention relates to a nanostructured carrier system for gene transport, in particular for the reduction of cytotoxic properties due to the use of a shell polymer and the resulting transport,...
DE102007063902B3 Aptamers that bind to a target molecule involved in hemostasis  
Aptamer that binds to a target molecule involved in hemostasis, the aptamer being an aptamer that binds to activated protein C, the aptamer having a dissociation constant KD binds to activated...
DE112015005320T5 Janus nanoparticles and methods for making the same  
The present invention is to provide a Janus nanoparticle, with a simple method, a drug may be encapsulated in, and a method of manufacturing the same. According to the present invention, a method...
DE102016000865A1 Functionalized metallic nanoparticles  
The invention relates to a vorfunktionalisiertes metallic nanoparticles (10) as a standardized basic element Biofunctionalized nanoparticles (40), with a thiol-reactive metallic nanoparticles...
DE102011000036B4 Recombinant plasmid-containing multicopy CpG motifs and their transformants for use as DNA adjuvants in avian vaccines  
A transformant of a recombinant plasmid containing multi-copy CpG motifs is disclosed. The recombinant plasmid containing an immunostimulatory polynucleotide having a sequence of the continuous...
DE102015216782B3 Use of microRNAs circulating in the blood serum or blood plasma for identifying biopsy-requiring patients and as markers for the differential diagnosis of individual non-ischemic cardiomyopathies or memory diseases of the heart  
The invention relates to the use of certain microRNAs circulating in the blood serum or blood plasma in the form of diagnostic profiles as markers in an in vitro method for distinguishing between...
DE102015216521B3 Use of specific genes for the diagnostic delineation of eosinophilic myocarditis from other fulminant inflammatory heart disease  
The invention relates to the use of a diagnostic profile for distinguishing an eosinophilic myocarditis from giant cell myocarditis and / or cardiac sarcoidosis in an in vitro method. The...
DE102015113038B3 Oligonucleotides and their use  
The invention relates to oligonucleotides which comprise or which consist of the nucleotide sequence SEQ ID NO 4, or oligonucleotides with nucleotide sequences homologous thereto, or...
DE102015005097A1 Chimeric antigen receptor (CAR) for cancer immunotherapy  
The invention relates to a chimeric antigen receptor (CAR) with a DNA sequence. Areas of application are medicine and the pharmaceutical industry. The subject of the invention is a new chimeric...
DE102014011258A1 Tumor-associated antigens for diagnosis and therapy  
The invention relates to a pharmaceutical composition comprising an agent which detects or inhibits the expression or activity of a tumor-associated antigen, and a method for the treatment and...
DE102014106327A1 VALLEY Effektornuklease to targeted knockout of HIV coreceptor CCR5  
The invention relates to a new VALLEY Effektornuklease (TALEN) for targeted knockout of the HIV coreceptor CCR5. In one aspect the invention thus provides a TAL Effektornuklease monomer comprising...
DE102014016541A1 The possibility of diseases especially degenerative cause cell wear, Gewebszersteurung, cell changes of any causes also genetic in nature, thus neoplasia WITH RIBONUKELINSÄUREN which were obtained from cells in to Mom  
In all mammals takes place a metamorphosis in the early embryonic phase. The ribonucleic acids formed during a metamorphosis worry as messengers in the cells in question for a conversion of this...
DE102013111099A1 Permanent gene correction by nukleotidmodifizierter messenger RNA  
The present invention relates to a nukleotidmodifizierte messenger RNA for the permanent correction of a genetic modification on a DNA. The invention also relates to a nukleotidmodifizierte...
DE102012104814A1 New RNA-molecule having a sequence with a specific length, useful as a target molecule for producing pharmaceutical composition for the treatment of infectious diseases  
RNA-molecule having a sequence with a length of at least 10 nucleotides, which consist of one of the sequences of SEQ ID NO: 1 (a 143 base pair sequence fully defined in the specification), SEQ ID...
DE102011114986A1 Spray system  
A spray system for producing an in-situ-forming matrix is ​​described which contains at least one lipophilic component, at least one polymer based on glycolic acid and lactic acid and at least one...
DE102011009470A1 Biologically active nucleotide molecules for targeted cell killing, use of the same and application kit  
The task was to kill cells in a wide range of applications, effectively, reliably and as effectively as possible in the organism, without the above-mentioned disadvantages of known chemical,...
DE102010036997A1 LOV domain protein for photosensitive disfunctionalization  
The present invention relates to the use of a protein comprising a LOV domain for the photosensitive defunctionalization of a molecule and a method for the photosensitive defunctionalization of a...
DE102011006610B3 Aptamers that are specific for immunoglobulin binding cell wall proteins  
The invention relates to an aptamer which binds to substances containing protein A, G or L, protein A, G or L and to microorganisms containing protein A, G or L, in particular Staphylococcus...
DE102011000036A1 Recombinant plasmid-containing multicopy CpG motifs and their transformants for use as DNA adjuvants in bird vaccines  
A transformant of a recombinant plasmid containing multicopy CpG motifs is disclosed. The recombinant plasmid containing an immunostimulatory polynucleotide that has a sequence of the continuous...
DE102010001332A1 Producing medicament comprises imaging amplified genome segments in isolated tumor sample, reproducing and sequencing fusion area of fused amplified genome segments in amplicons and providing sample, which specifically bind to fusion area  
Producing an individual specific medicament, comprises (a) high-resolution imaging of amplified genome segments in an isolated tumor sample using fine-tiling array, optionally after previous total...
DE102010007562A1 Dermatological, pharmaceutical composition suitable for oligonucleotides  
The present invention relates to a cosmetic and / or dermatological and or pharmaceutical composition for the topical application and application of oligonucleotides, in particular antisense...
DE102004009952B4 Procedure for the detection of sepsis  
Methods for in vitro differentiation of generalized, inflammatory, non-infectious states and generalized, inflammatory, infectious states, characterized in that it includes the following steps: a)...
DE102008032594A1 transfection  
The present invention relates to a transfection solution for the preparation of transfection complexes containing at least one buffer, preferably a HEPES buffer and at least a transfection...
DE102008020633A1 Nukleosiddi- and nucleoside prodrugs  
The invention relates to a prodrugs useful compounds, can be prepared therefrom pharmaceuticals and to pharmaceutical compositions and to pharmaceutical dosage forms and a method for preparing the...
DE102008013623A1 A pharmaceutical composition for diagnosis or treatment of diseases associated zinc finger protein  
The invention relates to nucleic acids to zinc finger proteins, for example, the human ZFY protein or to the human glioblastoma oncogene protein binding, and their uses.
DE102008013622A1 A pharmaceutical composition for the diagnosis or treatment of multiple myeloma  
The invention relates to pharmaceutical or diagnostic compositions containing at M antibody binding nucleic acids.
DE102007020554A1 Nucleic acid-containing cosmetic and / or pharmaceutical preparations for the treatment of epithelial integument  
The present invention relates to nucleic acid-containing cosmetic epithelial and / or pharmaceutical preparations for the treatment Reinforcement fabric and the use of nucleic acids as...
DE102007017290A1 Use of viologen dendrimer having 4, 4'-bipyridinium structure for e.g. transporting oligonucleotides, ribonucleic acid, and single and double stranded DNA in eukaryotic cells; and therapeutic methods in humans and animals  
Use of viologen dendrimer having 4, 4'-bipyridinium structure or higher generation for transporting oligonucleotides, ribonucleic acid, and single and double stranded DNA in eukaryotic cells; for...
DE10109466B4 Method and means for modification of human angiogenesis  
process to induce angiogenic processes in tissues of a mammalian organism, comprising the steps of: - Preparation of a ternary complex by complexing a nucleic acid molecule as a functional...
DE102006030366A1 Pharmaceutical composition useful for treating Parkinson's disease comprises a substance that specifically interacts with a homer1 gene  
Pharmaceutical composition comprises a substance that specifically interacts with a homer1 gene, with a regulatory protein of a homer1 gene, with a homer1 gene product or with a component of a...
DE102006007433A1 Immunostimulant adjuvant useful in vaccines against cancer or infectious diseases comprises a lipid-modified nucleic acid  
Immunostimulant adjuvant in the form of a lipid-modified nucleic acid is new. An independent claim is also included for a pharamceutical composition comprising an adjuvant as above, an active...
DE19858005B4 Synthetic nucleic acid particles  
Synthetic Particles formed from at least one oligonucleotide or a Derivative thereof and a protein having a molecular weight in the range 3900-4300, wherein the average diameter of the particle in...
DE102005036542A1 CTL prodrug  
The This invention relates to a polypeptide having preferably antitumoral and / or immunomodulatory Zytokineigenschaften through which Processing in vivo is activated, comprising a C-terminal...
DE102004054731A1 New pharmaceutical composition comprising an oligonucleotide that is adapted to target nucleic acids encoding CD40, useful for preventing or treating an inflammatory, immune or autoimmune disorder  
A pharmaceutical composition comprising an oligonucleotide that is adapted to target nucleic acids encoding CD40, thus modulating the expression of CD40 mammalian cells, and an amphoteric liposome...
DE60115222T2 COMBINING defibrotide AND G-CSF AND THEIR USE FOR ACTIVATION hematopoietic Progenitor Cells  
A description is given of a method of increasing the amount of stem cells and progenitor cells in circulation in the peripheral blood of a mammal; the method is characterised by the administration...
DE102005005642A1 A cosmetic or pharmaceutical compositions comprising nucleic acids consisting of the formation of stem-loop secondary structures appropriate sequences  
The This invention relates to cosmetic or pharmaceutical Preparations for the prophylaxis and / or treatment of epithelial integument, the nucleic acids included that the formation of stem-loop...
DE102005003788A1 siRNA molecules for the treatment of blood vessels  
The This invention relates to a nucleic acid molecule, a genetic construct, siRNA molecules and a composition or the nucleic acid molecule and / or the genetic construct and / the siRNA molecules...
DE102004059792A1 Multiparticulate pharmaceutical form comprising mucoadhesively formulated nucleic acid active ingredients, and a process for preparing the drug form  
The Invention relates to an oral, multi-particulate dosage form containing pellets, with a size in the range from 50 to 2500 microns, which are composed essentially of a) an inner matrix layer,...
DE102004056659A1 New pharmaceutical composition comprising an oligonucleotide that is adapted to target nucleic acids encoding CD40, useful for preventing or treating an inflammatory, immune or autoimmune disorder  
A pharmaceutical composition comprising an oligonucleotide that is adapted to target nucleic acids encoding CD40, thus modulating the expression of CD40 mammalian cells, and an amphoteric liposome...
DE102005000868A1 Compositions with inhibitors of prostaglandin and / or leukotriene synthesis in combination with stimulators of the release of cutaneous neuromediators  
object of the invention are topical compositions, at least in a suitable carrier an active ingredient, the prostaglandin synthesis and / or leukotriene synthesis inhibited, and at least one active...
DE102004025881A1 Oligoribonucleotides for influencing of hair growth  
oligoribonucleotides which induce the degradation of the mRNA of structures which in stimulating or inhibitory manner on the hair cycle influence, wherein the structures represent proteins and...
DE102004026309A1 Pharamzeutische composition for treating allergic diseases, pathological breathing path changes and cancer by modulating gene expression of Stat6  
The Invention relates to a pharmaceutical composition comprising a the Stat6 mRNA expression inhibiting oligonucleotide in physiologically effective dose.
DE102004010547A1 Oligoribonucleotides for the treatment of irritative and / or inflammatory skin conditions by RNA interference  
The duplexed oligoribonucleotide or a physiologically acceptable Salt thereof, which is capable of degradation of mRNA of one or more in inflammation and / or to induce irritation of the skin...
DE102004002351A1 New RNA aptamers specific for lipopolysaccharide-binding protein, useful for diagnosis and treatment of sepsis, inhibit the lipopolysaccharide-induced signaling cascade  
RNA aptamers (I), or their alleles and/or derivatives, that bind specifically to lipopolysaccharide-binding protein (LBP) are new. An independent claim is also included for a method for preparing...
DE10361502A1 Cosmetic or pharmaceutical preparations containing super structure-forming nucleic acid sequences  
The This invention relates to cosmetic or pharmaceutical Preparations for the prophylaxis and / or treatment of epithelial integument, contain the super structure-forming nucleic acid sequences...
DE10148828B4 Modulating the expression of STAT-1-dependent genes  
Pharmaceutical A composition comprising a double stranded DNA oligonucleotide, a strand of DNA a sequence according to SEQ ID NO: 1 to 32 or 34 to 40 or has a single-stranded nucleic acid molecule...
DE10346721A1 New oligonucleotides, useful for treating cancer, especially of the pancreas, are not species specific but induce apoptosis or inhibit proliferation  
Oligonucleotide (ON) that includes an arrangement of at least 6, preferably 8, consecutive nucleotides (nt) from (S1) is new. Oligonucleotide (ON) that includes an arrangement of at least 6,...
DE10341812A1 Differentially expressed in tumors gene products and their use  
According to the invention were Tumor-associated gene products expressed and coding the for nucleic acids identified. The present invention relates to the therapy and Diagnosis of diseases in...

Matches 1 - 50 out of 145 1 2 3 >